The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Two randomized, placebo-controlled phase 3 studies of ruxolitinib (Rux) + capecitabine (C) in patients (pts) with advanced/metastatic pancreatic cancer (mPC) after failure/intolerance of first-line chemotherapy: JANUS 1 (J1) and JANUS 2 (J2).
 
Herbert Hurwitz
Honoraria - Genentech/Roche; Lilly/ImClone
Consulting or Advisory Role - Acceleron Pharma; Bristol-Myers Squibb; Genentech/Roche; GlaxoSmithKline; Incyte; Lilly; Novartis; OncoMed; TRACON Pharma
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Macrogenics (Inst); NCI (Inst); Novartis (Inst); Regeneron (Inst); TRACON Pharma (Inst)
 
Eric Van Cutsem
Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Ipsen (Inst); Lilly (Inst); Merck Serono (Inst); Novartis (Inst); Roche (Inst); Sanofi (Inst)
 
Johanna C. Bendell
No Relationships to Disclose
 
Manuel Hidalgo
Stock and Other Ownership Interests - Champions Oncology
Honoraria - Celgene; MSD Oncology; Novartis; Pfizer
Consulting or Advisory Role - Celgene; Lilly/ImClone; Merck; Novartis; Pfizer
Research Funding - Celgene; Merck Serono; Pfizer
Travel, Accommodations, Expenses - Celgene; Merck; Pfizer
 
Chung-Pin Li
No Relationships to Disclose
 
Marcelo Garrido
No Relationships to Disclose
 
Teresa Mercade Macarulla
No Relationships to Disclose
 
Vaibhav Sahai
Honoraria - Celgene; Merrimack
Consulting or Advisory Role - Celgene
 
Ashwin Reddy Sama
Honoraria - OncoPlex Diagnostics
Research Funding - Bristol-Myers Squibb (Inst); Incyte (Inst); MedImmune (Inst); OncoMed (Inst); Precision Biologics (Inst)
Travel, Accommodations, Expenses - Celgene
 
Edward Greeno
No Relationships to Disclose
 
Kenneth H. Yu
Consulting or Advisory Role - Celgene; Merck Serono; Merrimack
 
Chris Verslype
No Relationships to Disclose
 
Fitzroy W. Dawkins
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Christopher Walker
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Jason Clark
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Eileen Mary O'Reilly
Consulting or Advisory Role - Aduro Biotech; Astellas Pharma (I); Celgene; Celsion (I); Cipla; Exelixis (I); Gilead Sciences; Hexal (I); IntegraGen (I); Jennerex (I); Lilly (I); MedImmune; Merrimack; Novartis (I); Pharmacyclics; Sanofi; Silenseed; Vicus Therapeutics
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Immunomedics (Inst); Incyte (Inst); Momenta Pharmaceuticals (Inst); Myriad Genetics (Inst); OncoMed (Inst); Polaris (Inst); Sanofi (Inst)